FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

PYOTT DAVID E I
2. Issuer Name and Ticker or Trading Symbol

ALLERGAN INC [ AGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chairman of the Board and CEO
(Last)          (First)          (Middle)

2525 DUPONT DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)

3/17/2015
(Street)

IRVINE, CA 92612
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/12/2015     G   V 114548   D $0   114548   I   By D & J Pyott Living Trust  
Common Stock   3/17/2015     D    165658.1405   (1) (2) (3) D   (1) 0   D    
Common Stock   3/17/2015     D    2180.2798   (1) D   (1) 0   I   By 401(k) Trust  
Common Stock   3/17/2015     D    2896.9356   (1) D   (1) 0   I   By Esop Trust  
Common Stock   3/17/2015     D    114548   (1) D   (1) 0   I   By D & J Pyott Living Trust  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   $58.55   3/17/2015     D         386800   (4)     (5) 2/2/2017   Common Stock   386800     (5) 0   I   By D & J Pyott Living Trust  
Employee Stock Option (Right to Buy)   $64.47   3/17/2015     D         410000      (5) 2/14/2018   Common Stock   410000     (1) 0   I   By D & J Pyott Living Trust  
Employee Stock Option (Right to Buy)   $75.58   3/17/2015     D         375000      (5) 2/17/2021   Common Stock   375000     (1) 0   I   By D & J Pyott Living Trust  
Employee Stock Option (Right to Buy)   $87.91   3/17/2015     D         312000      (5) 2/17/2022   Common Stock   312000     (1) 0   I   By D & J Pyott Living Trust  
Employee Stock Option (Right to Buy)   $40.16   3/17/2015     D         533000      (5) 2/20/2019   Common Stock   533000     (1) 0   I   By D & J Pyott Living Trust  
Employee Stock Option (Right to Buy)   $105.87   3/17/2015     D         303000      (5) 2/21/2023   Common Stock   303000     (1) 0   I   By D & J Pyott Living Trust  
Employee Stock Option (Right to Buy)   $59.13   3/17/2015     D         422400      (5) 2/22/2020   Common Stock   422400     (1) 0   I   By D & J Pyott Living Trust  
Employee Stock Option (Right to Buy)   $125.07   3/17/2015     D         257756      (5) 2/21/2024   Common Stock   257756     (1) 0   I   By D & J Pyott Living Trust  

Explanation of Responses:
( 1)  Pursuant to that certain Agreement and Plan of Merger dated November 16, 2014, (the "Merger Agreement") by and among the Issuer, Actavis, Plc ("Actavis) and a wholly-owned subsidiary of Actavis, the Issuer became an indirect wholly-owned subsidiary of Actavis upon consummation of the merger (the "Effective Date"). Each share of common stock was disposed of in exchange for $129.22 cash plus 0.3683 of an Actavis ordinary share, having a market value of $307.51 per share on the Effective Date.
( 2)  Includes 165,000 performance-based restricted stock units ("RSUs") previously reported on Form 4 filed on February 22, 2012. The RSUs vested in full on the Effective date pursuant to the terms of the Merger Agreement.
( 3)  Includes shares acquired under the Allergan, Inc. Dividend Reinvestment Plan.
( 4)  The option was previously reported as covering 193,400 shares at an exercise price of $117.10. The shares reported herein reflect a two-for-one stock split effected by the Issuer on June 22, 2007.
( 5)  Each option vested in full on the Effective Date and was cancelled in exchange for a cash payment equal to the number of shares subject to the option immediately prior to the merger, multiplied by the difference between (i) 0.3683 times $294.1509 (which represents the 10-day volume weighted average price of Actavis stock starting on the 11th trading day prior to the closing) plus $129.22 and (ii) the exercise price of the option, subject to the applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
PYOTT DAVID E I
2525 DUPONT DRIVE
IRVINE, CA 92612
X
Chairman of the Board and CEO

Signatures
/s/ Matthew J. Maletta, attorney-in-fact for David E.I. Pyott 3/19/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Allergan (NYSE:AGN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Allergan Charts.
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Allergan Charts.